Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (7.407%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Extension

20 Oct 2005 07:00

Angle PLC20 October 2005 For Immediate Release 20 October 2005 ANGLE plc CONTRACT EXTENSION ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology is pleased to announce that The Fairfax CountyEconomic Development Authority ("FCEDA") has extended its contract with ANGLETechnology Group US ('ANGLE Technology') through until June 2007. ANGLETechnology, headquartered in Virginia and formed in 1999, is the US technologydivision of ANGLE plc. The FCEDA promotes Fairfax County, Virginia, as aworld-class centre of commerce and trade and the technology hub of the eastcoast of the United States. The contract extension value is $0.47 million taking the total contract valuesince commencement in October 2001 to $1.92 million. Under the terms of thecontract, ANGLE Technology is to further develop, manage and provide fullon-going support to the BioAccelerator of Fairfax County, a business incubationprogram set-up in 2002 to develop early-stage biotechnology, biomedical andbioinformatics companies. The FCEDA created the BioAccelerator of Fairfax County to serve as a catalystfor the development of the bioscience industry in Northern Virginia. The role ofANGLE Technology ranges from business plan review, sales and marketing advice,and business mentoring, to recruitment activities and assistance with financingfor companies in the BioAccelerator. These companies represent convergingtechnologies that include bioscience, nanotechnology, environmental sciences,medical devices and software for biomedical research and healthcare. The ANGLE team also actively supports FCEDA marketing investment ininternational life science companies. Support for these companies focuses on theestablishment of US business operations and the development of targeted USmarketing activities. Andrew Newland, Chief Executive of ANGLE said: "Fairfax County is leading location in the United States for biomedicaltechnology. We are delighted that this important contract has again beenextended. In addition to its financial value, our work on the BioAcceleratorprovides us with a pipeline of opportunities for our expanding ventures businessin the Mid-Atlantic region of the US." For further information, please contact: ANGLE plc Tel: +44 (0)1483 295830Andrew Newland, Chief Executive Ian Griffiths, Finance Director Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors ANGLE plc - founded in 1994, ANGLE is an international venture management andconsulting company focusing on the commercialisation of technology and thedevelopment of technology-based industry. ANGLE creates, develops and advisestechnology businesses on its own behalf and for its clients. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.